Efficacy and safety of sonidegib in patients (pts) with nevoid basal cell carcinoma syndrome (NBCCS) - 21/04/16
John Lear, Manchester Royal Infirmary, Manchester, United Kingdom; Michael Migden, The University of Texas MD Anderson Cancer Center, Houston, TX, United States; Alexander Guminski, Royal North Shore Hospital, Sydney, Australia; Luc Dirix, Saint-Augustinus Ziekenhuis, Antwerp, Belgium; Anne Lynn S Chang, Stanford University School of Medicine, Redwood City, CA, United States; Patrick Burnett, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States; Dalila Sellami, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States; Ralf Gutzmer, Medizinische Hochschule, Hannover, Germany; Georg Stingl, Medical University of Vienna, Vienna, Austria; Reinhard Dummer, UniversitätsSpital Zürich, Zurich, Switzerland
Le texte complet de cet article est disponible en PDF.| Supported by Novartis Pharma AG, Basel, Switzerland. |
Vol 74 - N° 5S1
P. AB196 - mai 2016 Retour au numéro
Article précédent
- Effectiveness and diagnostic performance of dermoscopy on routine teledermatology-based skin cancer triage. Interim results of a randomized study
- Efficacy following discontinuation of sonidegib treatment in patients with locally advanced basal cell carcinoma (laBCC)
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?